Showing 1 - 10 of 14 for "" with applied filters
25 March 2026 by
When the members of a K-pop idol group affiliated with a Korean entertainment agency (the “Agency”) unilaterally claimed the termination of their exclusive agreement, the Agency filed a lawsuit against the group members, seeking (i) to confirm the validity of the exclusive agreement, and (ii) a preliminary injunction to prohibit the members from engaging in independent commercial activities and preserve the Agency’s status as their representative. Kim & Chang represented the Agency and obtained favorable court decisions on both claims.
25 March 2026 by
In January 2021, the Korea Fair Trade Commission (the “KFTC”) imposed a corrective order and administrative fine of KRW 26.6 billion on Naver (the “Corrective Order”) after finding that from approximately February 2012 to August 2020, Naver altered its algorithm for ranking product search results (the “search algorithm”) in Naver Shopping, a comparison shopping service, to favor sellers who are listed on Naver Smart Store, an open market platform service.
19 December 2025 by
On July 10, 2024, the Daegu High Court, Civil Division 2 (Presiding Judge, Tae-hyun Kim) rendered a judgment denying the establishment of a worker dispatch relationship between Public Institution A and the plaintiffs, who were workers of a subcontractor entrusted with performing facility maintenance work for Public Institution A (Daegu High Court Decision 2021Na21952, 21969 (consolidated) and 2021Na21976, all rendered on July 10, 2025).
19 December 2025 by
Kim & Chang’s Intellectual Property Practice successfully represented Pharmbio Korea Inc. (“Pharmbio Korea”), a domestic pharmaceutical company, in two patent invalidation lawsuits related to bowel cleanser tablets. The team secured victories at both the Intellectual Property Trial and Appeal Board (the “IPTAB”) and the Intellectual Property High Court (the “IP High Court”) by demonstrating that the two patents in question (the “Subject Patents”) could not have been easily developed by a person of ordinary skill in the art based on the prior art inventions.
19 December 2025 by
Kim & Chang secured a complete victory for a leading Korean mobility platform company (the “Plaintiff”) in a lawsuit against the Korea Fair Trade Commission (the “KFTC”). The lawsuit sought to revoke the KFTC’s corrective order and a fine of approximately KRW 27.1 billion. The KFTC had argued that the Plaintiff abused its market dominance by using an algorithm to unfairly favor its member taxis. The Seoul High Court accepted our arguments and overturned the KFTC’s dispositions entirely.
18 September 2025 by
The Cheongju District Court issued a ruling on April 9, 2025, denying a worker dispatch relationship between the plaintiffs, who were employees of Company B (i.e., a contractor that performed agricultural waste disposal services, the “Plaintiffs”), and Agency A (i.e., a quasi-governmental agency, the “Defendant”) (Cheongju District Court Decision 2022Gahap52546, April 9, 2025).
18 September 2025 by
Kim & Chang’s Environment Practice successfully won a case in its entirety on behalf of Company H, a large corporation in the shipbuilding and construction sector. This case was initiated by Company A, a real estate development company, against Company H at the Busan District Court, seeking costs of soil remediation and compensation for damages.
30 August 2024 by
Kim & Chang advised Glenwood Private Equity (“PE”) in connection with its acquisition of SK pucore Co., Ltd from SKC Ltd.
25 May 2023 by
Kim & Chang, using separate teams, advised both the buyer, MBK Partners, and the sellers, UCK Partners (formerly known as Unison Capital Korea) and individual shareholders, in connection with the purchase and sale of Medit Corporation (the “Target Company”).
31 January 2023 by
On October 7, 2021, Cigna group entered a stock purchase agreement to sell the equity interests of certain companies operating across seven countries, including LINA Life Insurance Co., Ltd. (“LINA Life”) and Cigna Korea, to Chubb group for USD $5.75 billion in cash (this event is hereby referred to as “the Transaction”). The Transaction was successfully completed on July 1, 2022. Kim & Chang advised Cigna Group in this transaction with respect to due diligence on LINA Life and other divested companies in Korea, review and execution of the stock purchase agreement and other legal advice necessary or required for the transaction.
